Overview

This trial is active, not recruiting.

Condition colorectal cancer
Treatments celecoxib, 5-fluorouracil, placebo, oxaliplatin, leucovorin
Phase phase 3
Sponsor Alliance for Clinical Trials in Oncology
Collaborator National Cancer Institute (NCI)
Start date June 2010
End date December 2019
Trial size 2500 participants
Trial identifier NCT01150045, CALGB-80702, CDR0000675693, U10CA031946

Summary

PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.

RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving oxaliplatin, leucovorin calcium, and fluorouracil is more effective with or without celecoxib in treating colon cancer.

United States Indiana, Kansas, and Maryland
Other Countries No locations recruiting